Fresenius Kabi (Anhui) Huirui Pharmaceutical

Fresenius Kabi (Anhui) Huirui Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company specializing in the development and manufacturing of intravenous (IV) drugs, with a focus on anesthesia and analgesia. In 2022, the global healthcare leader Fresenius Kabi acquired a majority stake in the company to expand its manufacturing footprint and product portfolio in the Chinese market. The company produces essential generic injectables, including propofol and etomidate, which are critical for surgical procedures and intensive care. Operating out of state-of-the-art facilities in Hefei, Anhui Province, the company adheres to international quality standards to support clinical nutrition and infusion therapy. This strategic integration combines local Chinese manufacturing expertise with Fresenius Kabi's global distribution network and clinical reach.